Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Where are We with current therapy?

J J Sung1

  • 1Division of Gastroenterology and Hepatology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, People's Republic of China.

Helicobacter
|June 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydrogel coated mesh decreases tissue reaction resulting from polypropylene mesh implant: implication in hernia repair.

Hernia : the journal of hernias and abdominal wall surgery·2016
Same author

Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells.

Oncogene·2015
Same author

miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.

Oncogene·2014
Same author

DACT2 is a functional tumor suppressor through inhibiting Wnt/β-catenin pathway and associated with poor survival in colon cancer.

Oncogene·2014
Same author

Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Endoscopy·2012
Same author

Interobserver reliability in the endoscopic diagnosis and grading of Barrett's esophagus: an Asian multinational study.

Endoscopy·2010
Same journal

Worldwide Phylogenetic and Clinical Risk Association of the Helicobacter pylori Outer Membrane Gene hopQ.

Helicobacter·2026
Same journal

Global Diversity of Helicobacter pylori Prophages Reveals Genetic Drivers of Virulence and Associations With Gastric Cancer.

Helicobacter·2026
Same journal

How to Improve Patient Adherence During Helicobacter pylori Diagnosis and Treatment.

Helicobacter·2026
Same journal

Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial.

Helicobacter·2026
Same journal

Efficacy and Safety of Fexuprazan-Based Modified High-Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial.

Helicobacter·2026
Same journal

Gastric Cancer Incidence After Helicobacter pylori Eradication and Lifestyle-Related Risk Factors: A Population-Based Cohort Study.

Helicobacter·2026
See all related articles

Effective Helicobacter pylori treatment involves one-week triple therapies, with proton pump inhibitors (PPIs) improving cure rates. Shorter regimens are not recommended, and retreatment strategies require further study, especially for children.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Helicobacter pylori infection remains a significant global health concern, with slow adoption of optimal therapies by the public and physicians.
  • Treatment for H. pylori has evolved, with current accepted regimens including one-week triple therapies with proton pump inhibitors (PPIs) or ranitidine bismuth citrate (RBC).

Purpose of the Study:

  • To review the evolution and current status of H. pylori treatment strategies.
  • To evaluate the efficacy of various therapeutic regimens, including first-line and retreatment options.
  • To highlight the need for optimized pediatric H. pylori treatment protocols.

Main Methods:

  • Review of existing evidence on H. pylori treatment regimens.
  • Analysis of data from studies such as MACH-2 regarding PPI and antimicrobial combinations.

Related Experiment Videos

  • Examination of retreatment strategies and pediatric treatment data.

    • Main Results:

    • One-week triple therapies with PPI/RBC are highly efficacious and well-tolerated.
    • Proton pump inhibitor (PPI) addition to antimicrobials significantly improves cure rates and combats resistance.
    • Shorter treatment durations (1-3 days) show unacceptably low efficacy; 10-14 days may be needed in the US.
    • Quadruple therapy achieves ~85% success in retreatment; switching metronidazole and clarithromycin is a sensible strategy.
    • Pediatric data is limited, but bismuth-based and PPI-based triple therapies show efficacy.

    Conclusions:

    • Established first-line therapies are effective, but optimal retreatment strategies require refinement.
    • Further large-scale studies are needed for rifabutin-containing regimens and high-dose PPI-amoxicillin dual therapy.
    • Developing optimal H. pylori therapy for children is crucial for long-term gastric cancer prevention.